Aditya Kumar Gupta1, Prasanth Srinivasan1, Gargi Das1, Jagdish Prasad Meena1, Pranay Tanwar2, Rachna Seth1. 1. Division of Pediatric Oncology, Department of Pediatrics, All India Institute of Medical Sciences New Delhi 110029, India. 2. Laboratory Oncology Unit, Dr. B. R. A. Institute Rotary Cancer Hospital, All India Institute of Medical Sciences New Delhi 110029, India.
Abstract
BACKGROUND: Engraftment of neutrophils and platelets after hematopoietic stem cell transplant (HSCT) is imperative for optimal outcomes. Eltrombopag has been used in adults after HSCT to boost platelet production. Its use in pediatric post HSCT patients has been limited. METHODS: The clinical and laboratory details of a post autologous HSCT patient were fetched by a retrospective review of the records. RESULTS: A 5-year old male child had primary thrombocytopenia post autologous HSCT for refractory Hodgkin lymphoma. Although the stem cell dose infused was adequate, the child had a delay in the engraftment of platelets. After ruling out the causes of post HSCT thrombocytopenia, eltrombopag was started for the child. With the use of eltrombopag, normal thrombopoiesis was restored in the child. CONCLUSION: Eltrombopag was effective and safe in overcoming post-HSCT primary thrombocytopenia in our patient. AJBR
BACKGROUND: Engraftment of neutrophils and platelets after hematopoietic stem cell transplant (HSCT) is imperative for optimal outcomes. Eltrombopag has been used in adults after HSCT to boost platelet production. Its use in pediatric post HSCT patients has been limited. METHODS: The clinical and laboratory details of a post autologous HSCT patient were fetched by a retrospective review of the records. RESULTS: A 5-year old male child had primary thrombocytopenia post autologous HSCT for refractory Hodgkin lymphoma. Although the stem cell dose infused was adequate, the child had a delay in the engraftment of platelets. After ruling out the causes of post HSCT thrombocytopenia, eltrombopag was started for the child. With the use of eltrombopag, normal thrombopoiesis was restored in the child. CONCLUSION:Eltrombopag was effective and safe in overcoming post-HSCT primary thrombocytopenia in our patient. AJBR
Authors: Shreeniwas S Raut; Sandip A Shah; Vijay V Sharanangat; Kamlesh M Shah; Kinnari A Patel; Asha S Anand; Shailesh S Talati; Harsha P Panchal; Apurva A Patel; Sonia K Parikh; Shilin N Shukla Journal: Indian J Hematol Blood Transfus Date: 2014-12-27 Impact factor: 0.900
Authors: Forat Lutfi; William Paul Skelton Iv; Yu Wang; Emma Rosenau; Nosha Farhadfar; Hemant Murthy; Christopher R Cogle; Ranadall Brown; John Hiemenz; John R Wingard; Maxim Norkin Journal: Hematol Oncol Stem Cell Ther Date: 2019-10-10
Authors: Paola Giordano; Giuseppe Lassandro; Angelica Barone; Simone Cesaro; Ilaria Fotzi; Fiorina Giona; Saverio Ladogana; Maurizio Miano; Antonio Marzollo; Margherita Nardi; Lucia Dora Notarangelo; Andrea Pession; Antonio Ruggiero; Giovanna Russo; Paola Saracco; Marco Spinelli; Alessandra Tolva; Assunta Tornesello; Valentina Palladino; Giovanni Carlo Del Vecchio Journal: Front Med (Lausanne) Date: 2020-02-28